- socially bharat
- September 25, 2024
Fujirebio Submits FDA Regulatory Filing for Lumipulse® G pTau 217/ß-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test as an Aid to Identify Patients With Amyloid Pathology Associated With Alzheimer’s Disease
TOKYO, Japan & MALVERN, Pa., United States: —Expected to Be First Commercially-Available Blood-Based In-Vitro Diagnostic for Patients Being Assessed for